Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 7/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.84 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.84 |
| ▸ | PGR | P06401 | 1/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.84 |
| ▸ | RXRA | P19793 | 1/20 | 0.84 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.84 |
| ▸ | CCKAR | P32238 | 1/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.84 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.84 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluvastatin SCHEMBL1786786 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL5056806 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL29380299 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL31002987 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL1147655 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL556763 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL6251405 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL41503 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL41663 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL1147661 | 0.99 | CYP2C9 (0.98) | CYP2C9KDM4EALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11952 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367217-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250367216-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250332254-A1 | METHODS FOR TREATING PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA | REGENERON PHARMA (US) | 2025-10-30 | — | — | US | claimed |
| US-20250264469-A1 | METHODS FOR IMPROVING OUTCOMES FOR HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS AT RISK FOR BRONCHIOLITIS OBLITERANS SYNDROME | CHILDREN'S HOSPITAL MEDICAL CENTER | 2025-08-21 | — | — | US | claimed |
| US-20250179219-A1 | CYCLODEXTRIN DIMERS, COMPOSITIONS THEREOF, AND USES THEREOF | CYCLARITY THERAPEUTICS INC (US) | 2025-06-05 | — | — | US | claimed |
| US-20250051418-A1 | VIRAL VECTORS AND USE THEREOF IN ADOPTIVE CELLULAR THERAPY | Immatics US, Inc. | 2025-02-13 | — | — | US | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-20240317684-A1 | PROCESS FOR PREPARING A CRYSTALLINE FORM OF FLUVASTATIN SODIUM SALT | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2024-09-26 | — | — | US | claimed |
| EP-4434967-A1 | PROCESS FOR PREPARING A CRYSTALLINE FORM OF FLUVASTATIN SODIUM SALT | F.I.S.- Fabbrica Italiana Sintetici S.p.A. (IT) | 2024-09-25 | — | — | EP | claimed |
| CN-118684614-A | Process for preparing crystalline form of fluvastatin sodium salt | F.I.S.-菲博利佳意大利合成面料股份公司 | 2024-09-24 | — | — | CN | claimed |
| CN-1131416-A | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents | SCHERING CORP (US) | 1996-09-18 | — | — | CN | claimed |
| EP-0457514-B1 | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor | SQUIBB & SONS INC (US) | 1996-08-21 | — | — | EP | claimed |
| EP-0671171-A1 | Use of HMG COA reductase inhibitor for the manufacture of a medicament for proventing or reducing risks of onset of cardiovascular events | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-09-13 | — | — | EP | claimed |
| WO-1994021230-A1 | METHOD AND COMPOSITIONS FOR DISRUPTING THE EPITHELIAL BARRIER FUNCTION | CELLEGY PHARMACEUTICALS, INC. (US) | 1994-09-29 | — | — | WO | claimed |
| EP-0508665-A2 | Use of ACE inhibitors for lowering serum cholesterol | E.R. SQUIBB & SONS, INC. (US) | 1992-10-14 | — | — | EP | claimed |
| EP-0482498-A2 | Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor | E.R. SQUIBB & SONS, INC. (US) | 1992-04-29 | — | — | EP | claimed |
| EP-0461548-A2 | Method for preventing a second heart attack employing and HMG CoA reductase inhibitor | E.R. SQUIBB & SONS, INC. (US) | 1991-12-18 | — | — | EP | claimed |
| EP-0457514-A1 | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor | E.R. SQUIBB & SONS, INC. (US) | 1991-11-21 | — | — | EP | claimed |
| EP-0401705-A2 | Use of an HMG CoA reductase inhibitor and/or a squalene synthetase inhibitor for treating peripheral atherosclerotic disease | E.R. Squibb & Sons, Inc. (US) | 1990-12-12 | — | — | EP | claimed |
| US-4915954-A | Dosage form for delivering a drug at two different rates | ALZA CORPORATION (US) | 1990-04-10 | — | — | US | claimed |